The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States
Author(s): Stephenson Kenna, Jones William, Stephenson Douglas M M
Issue: May/Jun 2006 - Hormone Replacement Therapy
View All Articles in Issue
Page(s): 175-183
Download in electronic PDF format for $65
Abstract: Prior to 1980, almost all drug advertising was directed to physicians, the parties responsible for prescribing medications to patients. Beginning in 1980, however, drug companies began advertising directly to patients by various means, specifically television and print advertisements and sponsorship of sports and similar events. During the last decade, as computers have become a common household item, the Internet is now another source of advertising for drug manufacturers. This change in advertising has been effective, since research has demonstrated that physicians’ prescribing decisions are, in fact, influenced heavily by patients’ requests for specific medications. In 1997, the US Food and Drug Administration devised specific guidelines for the television advertising of drugs produced by pharmaceutical manufacturers. Since youth and beauty have long been valued feminine qualities in the US, where menopausal women are assumed to suffer most from the effects of aging, pharmaceutical companies targeted women
Related Keywords:
Kenna Stephenson, MD, FAAFP, William Jones, MS, RPh, Douglas M. M. Stephenson, DO, drug advertising, drug promotion, commercials, hormone replacement therapy, HRT, US Food and Drug Administration, FDA, women, aging, drug marketing
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States
Stephenson Kenna, Jones William, Stephenson Douglas M M
|
May/Jun 2006
Pg. 175-183
|
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
|
Sep/Oct 2017
Pg. 356
|
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K
|
Jan/Feb 2013
Pg. 74-85
View Sample |
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
|
Jul/Aug 2016
Pg. 351
View Sample |
The Science Behind Hormone Replacement Therapy, Part 1
Wepfer Scott T
|
Nov/Dec 2001
Pg. 462-464
|
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
|
Jul/Aug 2015
Pg. 303-305
|
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
|
Nov/Dec 2015
Pg. 487-488
|
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
|
Jan/Feb 2023
Pg. 22-23
|
Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women
Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K, Pinson Barbara, Price Carol
|
Jul/Aug 2008
Pg. 295-304
|
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
|
Jul/Aug 2020
Pg. 296-297
|